Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 10093.034 | 0.8503 | 0.6930 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 10093.034 | 0.8289 | 0.6492 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 10093.034 | 0.6691 | 0.3235 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 10093.034 | 0.6161 | 0.2159 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.138 | uM | 10093.034 | 0.6925 | 0.3712 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 0.69 | uM | 10093.034 | 0.1581 | -0.6994 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 3.45 | uM | 10093.034 | 0.0176 | -0.9685 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 17.2 | uM | 10093.034 | 0.0119 | -0.9789 | 0.9732 | |
| MDA-MB-157 | TNBC | Basal B | Doxorubicin | TOP2 | TOP | 86.2 | uM | 10093.034 | 0.0004 | -0.9994 | 0.9732 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7886.007 | 1.0941 | 1.2920 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7886.007 | 1.0237 | 1.0722 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7886.007 | 0.9931 | 0.9790 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7886.007 | 0.8439 | 0.5466 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7886.007 | 0.8468 | 0.5547 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7886.007 | 0.4208 | -0.4610 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7886.007 | 0.6989 | 0.1625 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 17.2 | uM | 7886.007 | 0.6120 | -0.0494 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 86.2 | uM | 7886.007 | 0.6945 | 0.1512 | 0.6601 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.000221 | uM | 7886.043 | 1.0053 | 1.0153 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0011 | uM | 7886.043 | 0.9357 | 0.8164 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.00552 | uM | 7886.043 | 1.0036 | 1.0104 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.0276 | uM | 7886.043 | 0.9333 | 0.8098 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.138 | uM | 7886.043 | 0.9635 | 0.8951 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 0.69 | uM | 7886.043 | 0.8495 | 0.5792 | 0.6905 | |
| MDA-MB-175-VII | HR+ | Luminal | Doxorubicin | TOP2 | TOP | 3.45 | uM | 7886.043 | 0.6970 | 0.1858 | 0.6905 |